Longtime market bull Jeremy Siegel says investors could realize the market is behind the curve on interest rates.
VIDEO ON MSN MONEY
The burger chain's comparable global sales blew away analyst expectations for November.
The Home of the Golden Arches reported that global same-store sales increased 7.4% in November, surpassing the 4.6% gain Wall Street analysts expected. Sales in Europe and the U.S. rose 6.5% each, beating analysts' expectations. Not surprisingly, shares of the Oakbrook, Ill. company, which have risen more than 25% this year, rose 1.4% to $97.75 Thursday morning.
Expedia, Philip Morris and Las Vegas Sands are downgraded to 'neutral.'
Thursday's noteworthy upgrades include:
Few things are as bullish as stocks breaking above the ranges they have traded in, and big-cap names like McDonald's and IBM are hitting levels we’ve never seen before.
Sometimes it hits you like that. You will be watching the ticker go by and you will say, "Holy cow, did I just see a 4 handle on Home Depot (HD)?" Or, "Wait a second, did McDonald's (MCD) just take out $95? Is Verizon (VZ) finally out of the $35 orb? IBM (IBM) about to take out $200? No way!"
That's where we are right now: Stocks are hitting levels we haven't seen before -- not "haven't seen in a while" . . . never before.
CEO Jeff Bezos is focused on a far-reaching strategy, rather than just short-term results.
Amazon.com (AMZN) has been making massive investments in its future at the expense of short-term results.
With Jeff Bezos -- one of the few remaining tech visionaries -- at the helm, we’re willing to bet the online retailer will succeed in its far-reaching strategy.
The biopharmaceutical company's core product strategy is aimed at addressing major unmet medical needs.
Alnylam develops therapeutics based on a biological breakthrough technology known as ribonucleic acid interference (RNAi). Alnylam is currently using this know-how to build a pipeline of drug candidates to treat a wide array of diseases.
Federal regulators nix a proposal to make the pill available without a prescription to minors.
Teva Pharmaceutical (TEVA) hoped to have the first over-the-counter emergency contraceptive available to all ages Wednesday. It failed.
The U.S. Department of Health and Human Services rejected the company's application for Plan B One-Step -- known as the original morning-after pill -- to be available to consumers of all ages without a prescription. A positive verdict would have given Teva an exclusivity advantage it lost back in 2009, when a generic version of its drug hit the market.
The company reportedly is considering an online marketplace and fast-shipping service that may compete with Amazon.
The search giant is reportedly in negotiations with major retailers and shippers to create an online marketplace, taking Amazon (AMZN) head on. If Google's service manages to launch, it would directly compete against Amazon Prime, which provides customers free and quick shipping for a fixed annual fee.
Given the spate of new initiatives at Google, we believe the fast-shipping service will be a little more difficult to tackle, and question whether the company has the stomach for a business that could be very difficult.
The $100 million stake in Brazil's No. 2 airline will give Delta a way to win share in Latin America.
The company's commercial-free approach favors subscription revenue, but Sirius is trying to beef up ad sales as well.
Advertising accounts for only 4% of the stock's value by our estimates, but the company is making efforts to improve ad sales. The newest initiative, expected in the coming months, is SatRad 2.0, which is said to have a dual business model of subscription and advertising.
Sirius XM makes majority of its revenues through subscriptions, which are highly correlated with automobile sales.
Amazon's new tablet could pose a serious challenge to the iPad. And that’s just the beginning, with other competitors waiting in the wings.
Reviewers like "Captain Gadget" of the Huffington Post have dubbed Amazon’s (AMZN) new Kindle Fire a "tablet for dummies" compared to Apple's (AAPL) iPad. After all, you get less battery life, less connectivity, no camera and a smaller screen and hard drive, to name but a few subtractions.
But at $199, it also costs $300 less than the cheapest Apple iPad. And there seem to be plenty of folks out there willing to make the tradeoff -- enough for Canaccord Genuity analyst Michael Walkley to scale back his estimated iPad sales in the current quarter to 13 million from 14 million.
The government has suspended a plan to allow foreign companies to own as much as 51% of local supermarkets.
That's the kind of controversy India found itself in last month after giving Wal-Mart and other foreign companies the green light to own up to a 51% stake in supermarkets. Smaller shopkeepers worried that Wal-Mart, with its rock-bottom prices and competitive prowess, would put them out of business.
A look at the long-term prospects of 3 companies that have seen short interest rise.
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term. But when you look at individual stocks, you'll find plenty of stocks that lose money over the long haul. According to hedge fund institution Blackstar Funds, even with dividends included, between 1983 and 2006, 64% (nearly two-thirds) of stocks underperformed the Russell 3000, a broad-scope market index.
A large influx of short-sellers shouldn't be a damning factor to any company, but it could be a red flag from traders that something may not be as cut-and-dried as it appears.
An upcoming split into separate companies will unlock shareholder value.
ConocoPhillips (COP) plans to split the exploration and production (E&P) and refining and marketing segments into two stand-alone public companies.
Every two shares of COP will get you one share in the new Phillips 66. This upcoming spin-off, expected in the first half of next year, is likely to unlock shareholder value, and create two distinct market leaders in the process.
These small-cap biotechs have just confirmed bottom formations, setting up good buying opportunities on pullbacks.
By Tom Aspray, MoneyShow.com
Stocks have been performing well recently, though in trading early Wednesday stock index futures are slightly lower. Since the Nov. 25 close, the Spyder Trust (SPY) is up 8.5%, the SPDR Diamonds Trust (DIA), which tracks the Dow Industrials, is up 7.8%, and the iShares Russell 2000 Index Fund (IWM) is up 12.2%.
While the intermediate-term technical picture for the stock market is positive, short-term analysis suggests the rally may be running out of steam.
The stock price of the Sam Adams brewer has soared 40% in the past 3 months.
Boston Beer (SAM) is doing everything right this year.
Take a look at its extraordinary stock run. Since the beginning of October, shares have soared 40% to close at $101.31 Wednesday. The stock price has never been this high.
Why is the maker of Sam Adams beer so hot?
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
Fed keeps important 'considerable time' language in reference to short-term interest rates, but dissents and dots leave doubts.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] The major averages ended the midweek session with slim gains after showing some intraday volatility in reaction to the release of the latest policy directive from the Federal Open Market Committee. The S&P 500 added 0.1%, while the relative strength among small caps sent the Russell 2000 higher by 0.3%.
Equities spent the first half of the session near their flat lines as participants stuck to the sidelines ahead of the FOMC statement, which conveyed no changes to the ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|